Tanamachi Keisuke, Nishino Keisuke, Mori Natsuki, Suzuki Toshihiro, Tanuma Sei-Ichi, Abe Ryo, Tsukimoto Mitsutoshi
Department of Radiation Biosciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science.
Department of Biochemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Science.
Biol Pharm Bull. 2017 Jun 1;40(6):878-887. doi: 10.1248/bpb.b17-00083. Epub 2017 Mar 24.
Melanoma is highly malignant, and generally exhibits radioresistance, responding poorly to radiation therapy. We previously reported that activation of P2X7, P2Y6, and P2Y12 receptors is involved in the DNA damage response after γ-irradiation of human lung adenocarcinoma A549 cells. However, it is not clear whether these receptors are also involved in the case of melanoma cells, although P2X7 receptor is highly expressed in various cancers, including melanoma. Here, we show that P2X7 receptor antagonist enhances radiation-induced cytotoxicity in B16 melanoma cells in vitro and in vivo. We confirmed that these cells express P2X7 receptor mRNA and exhibit P2X7 receptor-mediated activities, such as ATP-induced pore formation and cytotoxicity. We further examined the radiosensitizing effect of P2X7 receptor antagonist Brilliant Blue G (BBG) in vitro by colony formation assay of B16 cells. γ-Irradiation dose-dependently reduced cell survival, and pretreatment with BBG enhanced the radiation-induced cytotoxicity. BBG pretreatment also decreased the number of DNA repair foci in nuclei, supporting involvement of P2X7 receptor in the DNA damage response. Finally, we investigated the radiosensitizing effect of BBG on B16 melanoma cells inoculated into the hind footpad of C57BL/6 mice. Neither 1 Gy γ-irradiation alone nor BBG alone suppressed the increase of tumor volume, but the combination of irradiation and BBG significantly suppressed tumor growth. Our results suggest that P2X7 receptor antagonist BBG has a radiosensitizing effect in melanoma in vitro and in vivo. BBG, which is used as a food coloring agent, appears to be a promising candidate as a radiosensitizer.
黑色素瘤具有高度恶性,通常表现出放射抗性,对放射治疗反应不佳。我们之前报道过,P2X7、P2Y6和P2Y12受体的激活参与了人肺腺癌A549细胞γ射线照射后的DNA损伤反应。然而,尽管P2X7受体在包括黑色素瘤在内的各种癌症中高表达,但尚不清楚这些受体在黑色素瘤细胞中是否也有参与。在此,我们表明P2X7受体拮抗剂在体外和体内均可增强辐射诱导的B16黑色素瘤细胞的细胞毒性。我们证实这些细胞表达P2X7受体mRNA,并表现出P2X7受体介导的活性,如ATP诱导的孔形成和细胞毒性。我们通过B16细胞的集落形成试验进一步检测了P2X7受体拮抗剂亮蓝G(BBG)在体外的放射增敏作用。γ射线照射剂量依赖性地降低细胞存活率,而用BBG预处理可增强辐射诱导的细胞毒性。BBG预处理还减少了细胞核中DNA修复灶的数量,支持P2X7受体参与DNA损伤反应。最后,我们研究了BBG对接种到C57BL/6小鼠后足垫的B16黑色素瘤细胞的放射增敏作用。单独1 Gy的γ射线照射或单独使用BBG均不能抑制肿瘤体积的增加,但照射与BBG联合使用可显著抑制肿瘤生长。我们的结果表明,P2X7受体拮抗剂BBG在体外和体内对黑色素瘤均有放射增敏作用。用作食用色素的BBG似乎是一种有前景的放射增敏剂候选物。